<DOC>
	<DOCNO>NCT01246843</DOCNO>
	<brief_summary>Patients advance kidney cancer GIST ( Gastro Intestinal Stromal Tumor : tumor intestine ) may eligible treatment one follow drug : sunitinib ( Sutent ® ) sorafenib ( Nexavar ® ) . These drug inhibit blood vessel formation cancer cell . These cancer cell hamper growth . To enlarge investigator knowledge effect side effect two medicine , University Medical Center St. Radboud lot research do . This study part . Patients receive sunitinib sorafenib tell sometimes feel less able concentrate , memory work properly less able imagine solution complex problem . Perhaps recognize symptom well . In many patient occurs , severe symptom cause , still unknown . The goal research examine memory , concentration knowledge processing work patient use sorafenib sunitinib . With research investigator hope get answer follow question : 1 . How common problem memory , concentration processing knowledge patient receive drug sunitinib sorafenib ? 2 . What problem memory , concentration processing knowledge use sunitinib sorafenib ? 3 . What could cause problem patient experience memory , concentration processing knowledge use sunitinib sorafenib ? 4 . Is link problem memory , concentration processing knowledge also experience fatigue mood patient ?</brief_summary>
	<brief_title>Evaluation Cognitive Function Patients With Sunitinib Sorafenib</brief_title>
	<detailed_description>In study focus subjective objective cognitive dysfunctioning patient metastatic cancer , treat sunitinib sorafenib . In clinical practice substantial part patient treat targeted therapy direct VEGF , mention problem concentrate memory function decrease . Relatives sometimes point behaviour patient slightly different start VEGF ( Vascular Endothelial Growth Factor ) inhibition . Pre-clinical study show VEGF influence growth recovery neuron .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients : patient metastatic renal cell cancer GIST treatment Sunitinib Sorafenib ≥ 8 week Karnofsky score &gt; 70 % age &gt; 18 year . write informed consent study Patient control selection patient metastatic renal cell cancer GIST n't treat yet ( interferon alfa interleukine 2 treatment allow &gt; 12 month ago . Karnofsky score &gt; 70 % age &gt; 18 year . write informed consent study Patients : contraindication treatment Sunitinib Sorafenib patient speak write Dutch language adequately know brain metastasis use psychiatric antiepileptic medication know cognitive disorder unrelated diagnosis medication use radiotherapy brain time past systemic chemotherapy last 12 month interferon alfa interleukin2 treatment operation last 3 month Stroke/TIA ( transient ischaemic attack ) Patient control section : patient speak write Dutch language adequately know brain metastasis use psychiatric antiepileptic medication know cognitive disorder unrelated diagnosis medication use radiotherapy brain time past systemic chemotherapy last 12 month interferon alfa interleukin2 treatment operation last 3 month stroke/TIA ( transient ischaemic attack )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>sorafenib</keyword>
	<keyword>cognitive functioning</keyword>
</DOC>